Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
← catalyst calendarNCT06526377 · readout ≤ 773 d
Sponsored by XBiotech, Inc. (industry) · XBIT — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
150estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Sep 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Axial Spondyloarthritis
- Ankylosing Spondylitis
- r-axSpA
- Nr-axSpA
Interventions
- Drug: vilamakitug — also filed as XB2001, Natrunix
- Drug: placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of participants achieving ASAS40.
measured Baseline to week 16
Permalink · XBIT's whole pipeline · Catalyst calendar · Every registered study · What changed